Anavex Life Sciences Corp.
NASDAQ:AVXLBiotechnology
-$0.04 today
- Market cap
- $66.69M
- Beta
- 1.12
- P/E (TTM)
- -5.9
- EPS (TTM)
- -$0.45
Volume 1.06M
Average 1.39M
AVXL Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Anavex Life Sciences Corp.NASDAQ: AVXL
Financing Cash Flow · Q1 FY2026 · quarter ended Dec 2025
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $36.32M rose 5030.4% year over year, ahead of the +256.9% change in trailing-twelve-month financing cash flow. Sequentially, it rose 262.6% from the prior quarter. Over 3 fiscal years it compounded at -23.8% a year.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +5030.4% holds above the trailing-twelve-month pace of +256.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 9.43M USD
- Year-over-year change
- -21.2%
- 4-year CAGR
- -50.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 9.43M | -21.2% |
| FY2024 | 2024-09-30 | 11.98M | -59.6% |
| FY2023 | 2023-09-30 | 29.65M | +39.3% |
| FY2022 | 2022-09-30 | 21.29M | -86.1% |
| FY2021 | 2021-09-30 | 153.24M | — |
Financing Cash Flow vs competitors
How AVXL compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +256.9% is the 4th highest of 10, against a peer median of +40.9%.
- Over three fiscal years its annual growth of -23.8% compares with a peer median of +33.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $845.81M USD | +63879.3% | -77.6% | — | |
| LTM Mar 2026 | $344.93M USD | +4594.2% | +454.4% | 970.5% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $189.81M USD | +0.4% | +60.3% | — |
| LTM Mar 2026 | $108.93M USD | +421.9% | — | 124.0% | |
| LTM Mar 2026 | $103.52M USD | +40.9% | +6.8% | — | |
| LTM Mar 2026 | $91.4M USD | -1574.2% | — | 102.2% | |
| LTM Mar 2026 | $70.71M USD | +60.2% | +172.5% | 3851.4% | |
| LTM Dec 2025 | $45.05M USD | +256.9% | -23.8% | — | |
| LTM Mar 2026 | €33.89M EUR | +4.1% | — | 21.7% | |
| LTM Mar 2026 | $446K USD | -99.2% | -49.5% | 0.6% | |
| Peer median (excluding AVXL) | — | +40.9% | +33.6% | 113.1% | |
Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (37.91M) | (47.98M) | (47.51M) | (43M) | (46.38M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.23M | 18.38M | 16.37M | 9.44M | 11.55M |
| Change in Working Capital | (706K) | 5.36M | 2.51M | 2.75M | (4.22M) |
| Accounts Receivables | (4.29M) | 5.94M | 484K | 260K | 1.64M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 751K | (914K) | 497K | 5.31M | (5.38M) |
| Other Working Capital | 2.83M | 331K | 1.52M | (2.81M) | (478K) |
| Other Non-Cash Items | 0 | 0 | 845K | 0 | 0 |
| Operating Cash Flow | (30.38M) | (24.24M) | (27.79M) | (30.81M) | (39.04M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 153.22M | 22M | 29.65M | 11.98M | 12.14M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 24K | (707K) | 29.65M | 11.98M | (2.71M) |
| Financing Cash Flow | 153.24M | 21.29M | 29.65M | 11.98M | 9.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 122.86M | (2.95M) | 1.87M | (18.84M) | (29.61M) |
| Free Cash Flow | (30.38M) | (24.24M) | (27.79M) | (30.81M) | (39.04M) |
Anavex Life Sciences Corp.
NASDAQ:AVXL
Intrinsic Alpha fair value
Locked
Current Price
$0.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.